IMU 1.89% 5.2¢ imugene limited

Ann: Phase 1 onCARlytics Trial Advances to Combination Arm, page-2

  1. 1,177 Posts.
    lightbulb Created with Sketch. 1348
    Good news for a Monday morning. Combo arm for OASIS open.
    In the monotherapy arm: Ovarian, breast and melanoma patients already treated.

    Interesting too that the announcement highlights Blincyto and now Yescarta and azer-cel as CD19-targetting CAR Ts for onCARlytics.

    GLTAH
    Last edited by GMT2: 11/03/24
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.